Vigil Neuroscience Strengthens Board of Directors with Appointment of Suzanne Bruhn, Ph.D.
CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the appointment of Suzanne Bruhn, Ph.D. to its Board of Directors.
- CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the appointment of Suzanne Bruhn, Ph.D. to its Board of Directors.
- Throughout my career, I have been drawn to unique targets such as microglia that have the potential to transform treatments for rare and underserved diseases.
- Vigils patient-centered approach to developing microglia-targeted therapeutics aligns with this vision as well as my background, Dr. Bruhn said.
- Dr. Bruhn currently serves on the Board of Directors of Pliant Therapeutics and Travere Therapeutics.